{"organizations": [], "uuid": "2080096e731ce079d5a4684451bc747c501de8cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-teva-announces-top-line-results-fr/brief-teva-announces-top-line-results-from-iii-studies-of-reslizumab-idUSFWN1PH0GJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:12:00.000+02:00", "replies_count": 0, "uuid": "2080096e731ce079d5a4684451bc747c501de8cf"}, "author": "", "url": "https://www.reuters.com/article/brief-teva-announces-top-line-results-fr/brief-teva-announces-top-line-results-from-iii-studies-of-reslizumab-idUSFWN1PH0GJ", "ord_in_thread": 0, "title": "BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / Updated 7 minutes ago BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab Reuters Staff 1 Min Read \nJan 22 (Reuters) - Teva Pharmaceutical Industries Ltd : \n* TEVA ANNOUNCES TOP-LINE RESULTS FROM PHASE III STUDIES OF SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA \n* TEVA - PHASE III REGISTRATION STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB (110 MG) IN A PRE-FILLED SYRINGE DID NOT MEET PRIMARY ENDPOINT \n* TEVA - PHASE III CLAIM-SUPPORT STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH OCS-DEPENDENT ASTHMA DID NOT MEET PRIMARY ENDPOINT \n* TEVA -NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE, NO CASES OF ANAPHYLAXIS RELATED TO RESLIZUMAB IDENTIFIED IN REVIEW OF DATA FROM STUDIES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T15:12:00.000+02:00", "crawled": "2018-01-22T16:02:29.006+02:00", "highlightTitle": ""}